After falling short in its pursuit of a Covid-19 vaccine, Altimmune Inc. is poised to disappoint investors once again, this time with its experimental weight-loss drug, according to a short report.
Shares of the biotechnology company tumbled 19% on Tuesday, after Sahm Adrangi’s Kerrisdale Capital Management revealed a new short position.
ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9c4CMaWlmaWNkvKOx0qKrsmWUp8KoecOerZ6kn6Wys3nApauipZ2qu6Z50qKlpKtdpLtut8SrqaKrlJa5pnnSoaarrF2Yrq24